Literature DB >> 17101198

Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague.

E D Williamson1, A J Stagg, S M Eley, R Taylor, M Green, S M Jones, R W Titball.   

Abstract

Protection against aerosol challenge with > 300 MLD of Yersinia pestis was observed 7 days after a single immunisation of mice with the F1+V vaccine. At day 60, mice were protected against injected challenge (10(7)MLD) in a vaccine dose-related manner. Recall responses to rV in splenocytes ex vivo at day 98 correlated significantly (p<0.001) with the immunising dose-level of V antigen; no memory response or anti-V serum IgG was detected in killed whole cell vaccine (KWCV) recipients. This may explain the susceptibility of KWCV recipients to aerosol challenge and the enhanced protection conferred by the F1+V sub-unit vaccine, particularly since the anti-F1 responses induced by either vaccine were similarly IgG1-polarised.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17101198     DOI: 10.1016/j.vaccine.2006.09.052

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.

Authors:  Julie L Boyer; Carolina Sofer-Podesta; John Ang; Neil R Hackett; Maria J Chiuchiolo; Svetlana Senina; David Perlin; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2010-07       Impact factor: 5.695

3.  Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Authors:  Shixia Wang; Jon D Goguen; Fusheng Li; Shan Lu
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

4.  Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols.

Authors:  Richard J Thomas; Daniel Webber; Aaron Collinge; Anthony J Stagg; Stephen C Bailey; Alejandro Nunez; Amanda Gates; Pramukh N Jayasekera; Rosa R Taylor; Steve Eley; Richard W Titball
Journal:  Infect Immun       Date:  2009-02-02       Impact factor: 3.441

5.  Mucosally delivered Salmonella typhi expressing the Yersinia pestis F1 antigen elicits mucosal and systemic immunity early in life and primes the neonatal immune system for a vigorous anamnestic response to parenteral F1 boost.

Authors:  Karina Ramirez; Alejandra V E Capozzo; Scott A Lloyd; Marcelo B Sztein; James P Nataro; Marcela F Pasetti
Journal:  J Immunol       Date:  2009-01-15       Impact factor: 5.422

6.  Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine.

Authors:  Christina L Airhart; Harold N Rohde; Carolyn J Hovde; Gregory A Bohach; Claudia F Deobald; Stephen S Lee; Scott A Minnich
Journal:  Vaccine       Date:  2008-08-21       Impact factor: 3.641

7.  Immune responses to plague infection in wild Rattus rattus, in Madagascar: a role in foci persistence?

Authors:  Voahangy Andrianaivoarimanana; Sandra Telfer; Minoarisoa Rajerison; Michel A Ranjalahy; Fehivola Andriamiarimanana; Corinne Rahaingosoamamitiana; Lila Rahalison; Ronan Jambou
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

8.  The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague.

Authors:  E D Williamson
Journal:  Adv Prev Med       Date:  2011-09-29

9.  Targeting of the Yersinia pestis F1 capsular antigen by innate-like B1b cells mediates a rapid protective response against bubonic plague.

Authors:  Yinon Levy; Yaron Vagima; Avital Tidhar; Moshe Aftalion; David Gur; Uri Nili; Theodore Chitlaru; Ayelet Zauberman; Emanuelle Mamroud
Journal:  NPJ Vaccines       Date:  2018-10-19       Impact factor: 7.344

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.